Search
Descriptor English: Zalcitabine
Descriptor Spanish: Zalcitabina
Descriptor zalcitabina
Entry term(s) 2',3'-didesoxicitidina
ddC (antiviral)
didesoxicitidina
Scope note: Compuesto dideoxinucleosídico en el cual el grupo hidroxilo 3' de la molécula de azúcar ha sido reemplazado por un hidrógeno. Esta modificación impide la formación de enlaces fosfodiéster necesarios para terminar las cadenas de ácido nucleico. El compuesto es un potente inhibidor de la replicación del VIH a bajas concentraciones, actuando como terminador de la cadena del ADN viral al unirse a la transcriptasa inversa. Su principal efecto secundario tóxico es la degeneración axonal que se produce en la neuropatía periférica.
Descriptor Portuguese: Zalcitabina
Descriptor French: Zalcitabine
Entry term(s): 2',3' Dideoxycytidine
2',3'-Dideoxycytidine
Dideoxycytidine
HIVID Roche
Hivid
NSC 606170
NSC-606170
NSC606170
ddC (Antiviral)
Tree number(s): D03.383.742.680.245.500.950
D13.570.230.329.950
D13.570.230.500.925
D13.570.685.245.500.950
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D016047
Scope note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antimetabolites
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Registry Number: 6L3XT8CB3I
CAS Type 1 Name: Cytidine, 2',3'-dideoxy-
Previous Indexing: Deoxycytidine/analogs & derivatives (1986-1989)
Dideoxynucleosides (1989)
Public MeSH Note: 94; was DIDEOXYCYTIDINE 1990-93
Online Note: use ZALCITABINE to search DIDEOXYCYTIDINE 1990-93
History Note: 94; was DIDEOXYCYTIDINE 1990-93
DeCS ID: 31821
Unique ID: D016047
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1990/01/01
Date of Entry: 1989/07/14
Revision Date: 2017/05/24
Zalcitabine - Preferred
Concept UI M0024532
Scope note A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Preferred term Zalcitabine
Entry term(s) 2',3' Dideoxycytidine
2',3'-Dideoxycytidine
Dideoxycytidine
ddC (Antiviral)
NSC-606170 - Narrower
Concept UI M0332662
Preferred term NSC-606170
Entry term(s) NSC 606170
NSC606170
Hivid - Narrower
Concept UI M0024533
Preferred term Hivid
Entry term(s) HIVID Roche



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey